PHILADELPHIA--(BUSINESS WIRE)--BioPhy, an innovative AI drug development platform, today announced the appointment of Scott Kobayashi as Senior Vice President of Sales. In this newly created role, Kobayashi will spearhead BioPhy's expansion in life sciences, public-private healthcare partnerships, financial services, and the public domain. This effort aims to assist organizations in navigating the intricate landscape of drug development and regulatory compliance.
With more than two decades of expertise in the life sciences sector, Kobayashi brings invaluable experience, most recently from his tenure at Delta Project Management, a life sciences consulting firm he co-founded and sold to Verista in 2022. Prior to this, he held pivotal consulting positions at pharmaceutical industry giants Pfizer, Genentech, and Fluor, specializing in business expansion, partnerships, and development strategies. Kobayashi will collaborate closely with BioPhy's executive team to expand its customer base, which already consists of several of the largest pharmaceutical companies.
“BioPhy has set itself apart from other biotech solutions with remarkable results in predicting and guiding clinical trial success. I am honored by the opportunity to join the BioPhy team and contribute to expanding its services, including forging partnerships with top pharmaceutical companies,” said Kobayashi. "It's a privilege to carry forward BioPhy’s mission, which aligns with my passion for transforming the process of developing and delivering new drugs to patients."
BioPhy's AI platform integrates scientific, clinical, and regulatory insights with a proprietary operational assessment model to evaluate biological feasibility and forecast the success of clinical trials, thereby optimizing capital allocation and hastening time-to-market. Over the past 27 months, the technology has accurately predicted the outcomes of over 2,000 clinical trials with an 80 percent success rate, underscoring BioPhy's ability to deliver substantial cost savings to pharmaceutical enterprises during clinical development. Through generative AI, BioPhy's platform facilitates critical functions essential to drug development, including clinical operations, regulatory compliance, and quality assurance.
"In just a few years, our products, BioPhyRX and BioLogicAI, have emerged as the preferred AI solutions for global pharmaceutical and life science firms seeking to analyze ongoing clinical trials and predict their success while navigating FDA regulations," said Dave Latshaw II, CEO and Co-Founder of BioPhy. “Scott brings a wealth of experience BioPhy. His consulting expertise, outstanding leadership, and strategic approach will be pivotal to the growth and success of the company. We are thrilled to have Scott join us and assist in building the partnerships necessary to expand our reach and bring the most promising drug candidates to market.”
BioPhy collaborates with leading pharmaceutical and life science enterprises, plus industry innovators such as EY, Avesta76, and Ambrose Healthcare, to identify promising drug targets and design efficient clinical trials. The company's expanding AI ecosystem for drug development comprises two flagship products:
- BioPhyRx: a generative AI solution designed to create a centralized, intuitive environment for accessing scientific and regulatory resources.
- BioLogicAI: a predictive AI engine that provides customized insights to aid life science companies through all stages of the drug development process including clinical trial endpoint predictability, indication selection, licensing, drug repurposing, asset acquisitions, and divestment.
The company has entered pilot and commercial agreements with leading pharmaceutical firms and secured $4.5 million in funding from various sources, including Metodora Ventures by Chelsea Clinton and Caroline Kassie, Audere Capital, TRCM, and notable biotechnology founders like Jeff Marrazzo, co-founder of Spark Therapeutics. For more information, please visit biophy.ai.
About BioPhy
Leveraging the possibilities of modern science and advanced technologies, BioPhy is committed to transforming the way promising drugs are identified, developed, and tested. With the help of its patent-pending predictive AI engine, BioPhy works to optimize the outcomes of clinical trials, reduce failure rates, and accelerate the pace of developing new drugs with the goal of improving the quality of healthcare outcomes across the globe.
